

2019 Awardees - Addiction

- ▶ **Caroline A. Arout, Ph.D.**, Columbia University Irving Medical Center and New York State Psychiatric Institute, for assessing effects of repeated high-cannabidiol cannabis administration on experimental pain and abuse liability in humans
- ▶ **Gregory F. Corder, Ph.D.**, University of Pennsylvania, for research on prevention of neurodevelopmental disabilities associated with neonatal opioid withdrawal
- ▶ **Victor Philippe Mathis, Ph.D.**, Icahn School of Medicine at Mount Sinai, for research defining the role of cortical inputs to the habenula in the control of midbrain dopamine neurons and addiction-related behaviors
- ▶ **Cody A. Siciliano, Ph.D.**, Vanderbilt University, for research assessing neural mechanisms of cognitive dysfunction and alcohol abuse vulnerability

2019 Awardees - Schizophrenia

- ▶ **Michael S Breen, Ph.D.**, Icahn School of Medicine at Mount Sinai, for research on functional and translational implications of A-to-I RNA editing in schizophrenia
- ▶ **Xi Chen, Ph.D.**, McLean Hospital, Harvard Medical School, for In vivo research observing brain lactate changes in first-episode schizophrenia using 3-T magnetic resonance spectroscopy
- ▶ **Amanda McCleery, Ph.D.**, University of California Los Angeles (UCLA) Semel Institute for Neuroscience and Human Behavior, for research on the impact of aripiprazole medication adherence on learning and neuroplasticity in recent-onset schizophrenia: A comparison of long-acting injectable and oral formulations
- ▶ **Jose M Rubio, M.D.**, Zucker School of Medicine at Hofstra/Northwell, for assessing the fluctuations in resting state functional connectivity associated with psychosis relapse during antipsychotic maintenance

2018 Awardees - Addiction

- ▶ **Lais Fernanda Berro, Ph.D.**, University of Mississippi Medical Center, for preclinical research on quantitative pharmacology and pharmacotherapeutics for opioid and benzodiazepine co-abuse
- ▶ **Mehdi Farokhnia, M.D.**, Section on Clinical Psychoneuroendocrinology and Neuropsychopharmacology (CPN), National Institute on Alcohol Abuse and Alcoholism (NIAAA) and National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), for examining the neurobiological correlates and pharmacotherapeutic implications of the GLP-1 system in relation to alcohol use
- ▶ **Sarah L. Withey, Ph.D.**, Harvard Medical School, McLean Hospital, for assessing the effects of continuous exposure to naltrexone on the behavior and reward circuitry involved in opioid addiction relapses in non-human subjects